中文 |English

首页 > 教职员工 > > 周启璠

教研序列研究序列访问教授行政人员

  • 周启璠

    研究助理教授（硕士生导师）
    • 邮箱:zhouqf@sustech.edu.cn

    办公室:南方科技大学创园5栋605

    个人主页:

    http://faculty.sustech.edu.cn/zhouqf

    • 基本介绍
    • 研究方向
    • 学术成果
    • 其它信息

    周启璠，浙江台州人，现任南方科技大学格拉布斯研究院研究助理教授（副研究员），生物技术副高级工程师。2019年于沈阳药科大学获得药物化学专业博士学位。主要从事肿瘤、病毒和炎症相关疾病的小分子创新药物研究与开发。结合AI生成和筛选模型，针对新靶点或临床药物缺乏疾病进行新型小分子药物开发。广东省化学学会人工智能委员化学专业委员会委员、广东省药学会药物化学专业委员会委员、《沈阳药科大学学报》编委。作为骨干成员参与新冠口服药SHEN26的研发，该药目前进入上市申请阶段。主持国家自然科学基金C和深圳市面上项目，近5年在JMC, STM, STTT, APSB等期刊发表SCI论文30余篇，申请发明专利27项，其中作为主要发明人获得中国专利授权17项 。

    1. 基于病毒共性靶标的小分子药物开发；

    2. 结合AI模型，针对新靶点或临床药物缺乏疾病进行新型小分子药物开发；

    3. 药物临床前研究

    1. Yuanguang Chen 1, Sumei Yang 1, Xingyu Zhou 1, Hongyang Yi 1, Dizhen Liang a, Guanguan Li, Xiang Liu, Peisen Zheng, Yongqing Liu, Xinshan Deng, Xumu Zhang,* Qifan Zhou,** Hongzhou Lu***. Ligand-based design and optimization of tecovirimat derivatives as potent antiviral agents against monkeypox virus. European Journal of Medicinal Chemistry, 2026, 303, 118447.
    2. Yujian Yang, Binhao Rong, Yongqing Liu, Haowei Li, Dizhen Liang, Yuanmei Wen, Qifan Zhou,* and Xumu Zhang.* Development of an Optimized Synthetic Process for Onradivir Featuring a “One-Pot” Miyaura-Suzuki Coupling Reaction. Organic Process Research & Development, 2025, 29, 2674-2684.
    3. Yuanmei Wen,# Jun Zhou,# Fan Pan, Peisen Zheng, Fengxia Zhong, Sidi Yang, Qianhan Ma, Deyin Guo, Xumu Zhang, Qifan Zhou,* and Yingjun Li*. Identification and Evaluation of Non-Nucleosidic MTase Inhibitors against SARS-CoV‑2 nsp14 with Lower-Micromolar Anti-Coronavirus Activity. ACS Infectious Diseases, 2025, 11(8): 2145-2156.
    4. Yuanguang Chen, # Yongqing Liu, # Guanguan Li, # Chao Peng, Dizhen Liang, Sidi Yang, Peisen Zheng, Shuo Li, Deyin Guo, Qifan Zhou,* and Xumu Zhang *. Preclinical characterization and anti-RSV efficacy of an oral C-nucleoside derivative. Acta Pharmaceutica Sinica B, 2025, 15(12): 6727-6730.
    5. Peisen Zheng, Guanguan Li, Yuanguang Chen, Shuo Li, Sidi Yang, Deyin Guo, Qifan Zhou* and Xumu Zhang*. Mini review: SHEN26, a novel oral antiviral drug for COVID-19 treatment. Bioorganic & Medicinal Chemistry Letters, 2025, 124, 130243.
    6. Yongqing Liu1, Haobin Li1, Dizhen Liang1, Yuanguang Chen, Kunyu Lu, Hongqi Tao, Yuanmei Wen, Fan Pan, Xumu Zhang, Shuwen Liu* and Qifan Zhou*. Harnessing hydrophobic tag technology to combat drug-resistant influenza: design, synthesis and potency of oseltamivir-derived HyTTDs. New Journal of Chemistry, 2025, 49, 5489-5504.
    7. Yongzhi Chen1, Kunyu Lu1, Binhao Rong1, Yuanmei Wen, Guanguan Li, Shuo Li, Deyin Guo, Qifan Zhou*, Shuwen Liu*, Xumu Zhang*. Discovery of Novel Thiophene-Based Baloxavir Derivatives as Potent Cap-Dependent Endonuclease Inhibitors for Influenza Treatment. Journal of Medicinal Chemistry, 2024, https://doi.org/10.1021/acs.jmedchem.4c01979.
    8. Fan Pan1, Qifan Zhou*,1, Ming Yan1, Sidi Yang1, Ruiyu Hu, Yongzhi Chen, Yuanmei Wen, Yang Chao, Cailing Xie, Weixin Ou, Yingjun Li, Hongmin Zhang*, Deyin Guo*, Xumu Zhang*. Development of pyrimidone derivatives as nonpeptidic and noncovalent 3-chymotrypsin-like protease (3CLpro) inhibitors with anti-coronavirus activities. Bioorganic Chemistry, 2024, 154, 107988.
    9. Yongzhi Chen1, Qifan Zhou**,1, Fan Pan, Binhao Rong, Renwei Xiao, Yuanmei Wen, Jingyuan Song, Zhengchao Tu, Shuwen Liu****, Yingjun Li***, Xumu Zhang*. Synthesis and anti-influenza virus activity of substituted dibenzoxepine-based baloxavir derivatives. European Journal of Medicinal Chemistry, 2024, 280, 116922.
    10. Qishu Chen1, Qifan Zhou1,*, Sidi Yang1, Fan Pan, Hongqi Tao, Yuanmei Wen, Yang Chao, Cailing Xie, Weixin Ou, Deyin Guo*, Yingjun Li*, Xumu Zhang*. Identification of adenosine analogues as nsp14 N7‑methyltransferase inhibitors for treating coronaviruses infection. Bioorganic Chemistry, 2024, 153, 107894.
    11. Qishu Chen1, Qifan Zhou1, Guanguan Li, Shuo Li, Yingjun Li* and Xumu Zhang*. Optimized kilogram-scale synthesis and impurity identification of SHEN26 (ATV014) for treating COVID-19. Organic Process Research & Development. 2024, 28, 2188-2195.
    12. Qifan Zhou1, Sidi Yang1, Liu Cao1, Yang Yang1, Tiefeng Xu, Qishu Chen, Hongzhou Lu, Yingjun Li*, Deyin Guo*, Xumu Zhang*. Preclinical characterization of SHEN26, an oral cyclohexanecarboxylate prodrug of 1′-CN-4-aza-7,9-dideazaadenosine C-nucleoside for the treatment of SARS-CoV-2. Signal Transduction and Targeted Therapy, 2023, 8, 27. 
    13. Qifan Zhou1, Yinzhu Luo1, Yujun Zhu1, Qishu Chen, Jingfei Qiu, Feng Cong*, Yingjun Li*, Xumu Zhang*. Nonsteroidal anti-inflammatory drugs (NSAIDs) and nucleotide analog GS-441524 conjugates with potent in vivo efficacy against coronaviruses. European Journal of Medicinal Chemistry, 2023, 249.
    14. Liu Cao1, Yingjun Li1, Sidi Yang1, Guanguan Li1, Qifan Zhou1, Jing Sun1, et al. The adenosine analogue prodrug ATV006 is orally bioavailable and has potent preclinical efficacy against SARS-CoV-2 and its variants. Science Translational Medicine, 2022, 14, eabm7621. 
    15. Qifan Zhou, Lina Jia, Fangyu Du, Xiaoyu Dong, Wanyu Sun, Lihui Wang, Guoliang Chen*. Design, synthesis and biological activities of pyrrole-3-carboxamide derivatives as EZH2 (enhancer of zeste homologue 2) inhibitors and anticancer agents. New Journal of Chemistry, 2020, 44, 2247-2255. 
    16. Fangyu Du1, Qifan Zhou1, Wenjiao Sun, Cheng Yang, Chunfu Wu, Lihui Wang* and Guoliang Chen*. 5-Hydroxyindole-based EZH2 inhibitors assembled via TCCA-catalyzed condensation and Nenitzescu reactions. Molecules, 2020, 25, 2059–2083.
    17. Qifan Zhou, Fangyu Du, Yuanguang Chen, Yang Fu, Wenjiao Sun, Ying Wu, Guoliang Chen*. L-(-)-Quebrachitol as a ligand for selective copper (0)-catalyzed N‑arylation of nitrogen-containing heterocycles. Journal of Organic Chemistry, 2019, 84, 8160–8167. 
    18. Qifan Zhou, Fangyu Du, Yuanguang Chen, Yang Fu, Guoliang Chen*. “On Water” promoted N-arylation reactions using Cu (0)/myo-inositol catalytic system. Tetrahedron Letters, 2019, 60, 1938–1941. 
    19. Chunling Yuan1, Xiaoli Guo1, Qifan Zhou1, Fangyu Du, Xiaoyu Zhou, Peng Liu, Tianyan Chi, Xuefei Ji, Jinheng Gao, Chengwen Chen, Hongli Lang, Jia Xu, Danyang Liu, Yang Yang, Shimeng Qiu, Guoliang Chen* and Libo Zou*. OAB-14, a novel small molecule, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing -amyloid clearance in APP/PS1 mice. BBA-Molecular Basis of Disease, 2019, 1865, 161–180. 
    20. Yajie Shi1, Qifan Zhou1, Fangyu Du, Yang Fu, Yang Du, Ting Fang and Guoliang Chen*. Iridium-catalyzed intramolecular C-N and C-O/S cross-coupling reactions: Preparation of benzoazole derivatives. Tetrahedron Letters, 2019, 60, 151082–151090. 
    21. Fangyu Du1, Qifan Zhou1, Yang Fu, Yuanguang Chen, Ying Wu* and Guoliang Chen*. Copper(II)-catalyzed C–N coupling of aryl halides and N-nucleophiles promoted by quebrachitol or diethylene glycol. Synlett, 2019, 30, 2161–2168. 
    22. Fangyu Du1, Qifan Zhou1, Yang Fu, Hanqi Zhao, Yuanguang Chen and Guoliang Chen*. tert-Butyl(3-cyano-4,6-dimethylpyridin-2-yl)carbonate as a green and chemoselective N–tert-butoxycarbonylation reagent. New Journal of Chemistry, 2019, 43, 6549–6554. 
    23. Fangyu Du, Qifan Zhou, Xiaoxiao Fu, Yajie Shi, Yuanguang Chen, Wuhong Fang, Jingyu Yang* and Guoliang Chen*. Synthesis and biological evaluation of 2,2-dimethylbenzopyran derivatives as potent neuroprotection agents. RSC Advances, 2019, 9, 2498–2508. 
    24. Fangyu Du, Qifan Zhou, Wenjiao Sun and Guoliang Chen*. Targeting cancer stem cells in drug discovery: Current state and future perspectives. World Journal of Stem Cells, 2019, 11, 398–420. 
    25. Fangyu Du, Qifan Zhou, Yajie Shi, Miao Yu, Wenjiao Sun and Guoliang Chen*. Synthesis of regorafenib through novel preparation of the intermediate 4-amino-3-fluorophenol via fries and Beckman rearrangements. Synthetic Communications, 2019, 49, 576–586. 
    26. Caijiao Wu1, Qifan Zhou1, Dake Song, Hui Li, Changshun Bao, Xuelong Liu, Xuefei Bao and Guoliang Chen*. An improved process for the preparation of pimavanserin tartrate. Journal of Chemical Research, 2019, 43, 480-485. 
    27. Qifan Zhou, Chen Peng, Fangyu Du, Linbo Zhou, Yajie Shi, Yang Du, Dongdong Liu, Wenjiao Sun, Meixia Zhang*, Guoliang Chen*. Design, synthesis and activity of BBI608 derivatives targeting on stem cells. European Journal of Medicinal Chemistry, 2018, 151, 39-50. 
    28. Qifan Zhou, Fangyu Du, Xinjie Liang, Wenqiang Liu, Ting Fang and Guoliang Chen*. Zinc (II)-mediated selective O-benzylation of 2-oxo-1,2-dihydropyridines systems. Molecules, 2018, 23, 1784-1798. 
    29. Qifan Zhou, Fangyu Du, Yajie Shi, Wenqiang Liu, Dongdong Liu and Guoliang Chen*. An efficient protocol for the production of pymetrozine via a new synthetic strategy. Journal of Chemical Research, 2018, 42, 395-446. 
    30. Qifan Zhou, Fangyu Du, Yajie Shi, Ting Fang, Guoliang Chen*. The synthesis and analysis of 1-methyl-4-phenyl-1H-imidazol-2-amine and by-products. Journal of Chemical Research, 2018, 42, 608–610. 
    31. Fangyu Du, Qifan Zhou, Dongdong Liu, Ting Fang, Yajie Shi, Yang Du, Guoliang Chen*. Dimerization of aromatic compounds using palladium-carbon catalyzed Suzuki–Miyaura cross-coupling by one-pot synthesis. Synlett, 2018, 29, 779-784.

周启璠研究助理教授（硕士生导师）

邮箱:zhouqf@sustech.edu.cn

办公室:南方科技大学创园5栋605

个人主页:

http://faculty.sustech.edu.cn/zhouqf

  • 基本介绍
  • 研究方向
  • 代表性论文
  • 其它信息

周启璠，浙江台州人，现任南方科技大学格拉布斯研究院研究助理教授（副研究员），生物技术副高级工程师。2019年于沈阳药科大学获得药物化学专业博士学位。主要从事肿瘤、病毒和炎症相关疾病的小分子创新药物研究与开发。结合AI生成和筛选模型，针对新靶点或临床药物缺乏疾病进行新型小分子药物开发。广东省化学学会人工智能委员化学专业委员会委员、广东省药学会药物化学专业委员会委员、《沈阳药科大学学报》编委。作为骨干成员参与新冠口服药SHEN26的研发，该药目前进入上市申请阶段。主持国家自然科学基金C和深圳市面上项目，近5年在JMC, STM, STTT, APSB等期刊发表SCI论文30余篇，申请发明专利27项，其中作为主要发明人获得中国专利授权17项 。

1. 基于病毒共性靶标的小分子药物开发；

2. 结合AI模型，针对新靶点或临床药物缺乏疾病进行新型小分子药物开发；

3. 药物临床前研究

  1. Yuanguang Chen 1, Sumei Yang 1, Xingyu Zhou 1, Hongyang Yi 1, Dizhen Liang a, Guanguan Li, Xiang Liu, Peisen Zheng, Yongqing Liu, Xinshan Deng, Xumu Zhang,* Qifan Zhou,** Hongzhou Lu***. Ligand-based design and optimization of tecovirimat derivatives as potent antiviral agents against monkeypox virus. European Journal of Medicinal Chemistry, 2026, 303, 118447.
  2. Yujian Yang, Binhao Rong, Yongqing Liu, Haowei Li, Dizhen Liang, Yuanmei Wen, Qifan Zhou,* and Xumu Zhang.* Development of an Optimized Synthetic Process for Onradivir Featuring a “One-Pot” Miyaura-Suzuki Coupling Reaction. Organic Process Research & Development, 2025, 29, 2674-2684.
  3. Yuanmei Wen,# Jun Zhou,# Fan Pan, Peisen Zheng, Fengxia Zhong, Sidi Yang, Qianhan Ma, Deyin Guo, Xumu Zhang, Qifan Zhou,* and Yingjun Li*. Identification and Evaluation of Non-Nucleosidic MTase Inhibitors against SARS-CoV‑2 nsp14 with Lower-Micromolar Anti-Coronavirus Activity. ACS Infectious Diseases, 2025, 11(8): 2145-2156.
  4. Yuanguang Chen, # Yongqing Liu, # Guanguan Li, # Chao Peng, Dizhen Liang, Sidi Yang, Peisen Zheng, Shuo Li, Deyin Guo, Qifan Zhou,* and Xumu Zhang *. Preclinical characterization and anti-RSV efficacy of an oral C-nucleoside derivative. Acta Pharmaceutica Sinica B, 2025, 15(12): 6727-6730.
  5. Peisen Zheng, Guanguan Li, Yuanguang Chen, Shuo Li, Sidi Yang, Deyin Guo, Qifan Zhou* and Xumu Zhang*. Mini review: SHEN26, a novel oral antiviral drug for COVID-19 treatment. Bioorganic & Medicinal Chemistry Letters, 2025, 124, 130243.
  6. Yongqing Liu1, Haobin Li1, Dizhen Liang1, Yuanguang Chen, Kunyu Lu, Hongqi Tao, Yuanmei Wen, Fan Pan, Xumu Zhang, Shuwen Liu* and Qifan Zhou*. Harnessing hydrophobic tag technology to combat drug-resistant influenza: design, synthesis and potency of oseltamivir-derived HyTTDs. New Journal of Chemistry, 2025, 49, 5489-5504.
  7. Yongzhi Chen1, Kunyu Lu1, Binhao Rong1, Yuanmei Wen, Guanguan Li, Shuo Li, Deyin Guo, Qifan Zhou*, Shuwen Liu*, Xumu Zhang*. Discovery of Novel Thiophene-Based Baloxavir Derivatives as Potent Cap-Dependent Endonuclease Inhibitors for Influenza Treatment. Journal of Medicinal Chemistry, 2024, https://doi.org/10.1021/acs.jmedchem.4c01979.
  8. Fan Pan1, Qifan Zhou*,1, Ming Yan1, Sidi Yang1, Ruiyu Hu, Yongzhi Chen, Yuanmei Wen, Yang Chao, Cailing Xie, Weixin Ou, Yingjun Li, Hongmin Zhang*, Deyin Guo*, Xumu Zhang*. Development of pyrimidone derivatives as nonpeptidic and noncovalent 3-chymotrypsin-like protease (3CLpro) inhibitors with anti-coronavirus activities. Bioorganic Chemistry, 2024, 154, 107988.
  9. Yongzhi Chen1, Qifan Zhou**,1, Fan Pan, Binhao Rong, Renwei Xiao, Yuanmei Wen, Jingyuan Song, Zhengchao Tu, Shuwen Liu****, Yingjun Li***, Xumu Zhang*. Synthesis and anti-influenza virus activity of substituted dibenzoxepine-based baloxavir derivatives. European Journal of Medicinal Chemistry, 2024, 280, 116922.
  10. Qishu Chen1, Qifan Zhou1,*, Sidi Yang1, Fan Pan, Hongqi Tao, Yuanmei Wen, Yang Chao, Cailing Xie, Weixin Ou, Deyin Guo*, Yingjun Li*, Xumu Zhang*. Identification of adenosine analogues as nsp14 N7‑methyltransferase inhibitors for treating coronaviruses infection. Bioorganic Chemistry, 2024, 153, 107894.
  11. Qishu Chen1, Qifan Zhou1, Guanguan Li, Shuo Li, Yingjun Li* and Xumu Zhang*. Optimized kilogram-scale synthesis and impurity identification of SHEN26 (ATV014) for treating COVID-19. Organic Process Research & Development. 2024, 28, 2188-2195.
  12. Qifan Zhou1, Sidi Yang1, Liu Cao1, Yang Yang1, Tiefeng Xu, Qishu Chen, Hongzhou Lu, Yingjun Li*, Deyin Guo*, Xumu Zhang*. Preclinical characterization of SHEN26, an oral cyclohexanecarboxylate prodrug of 1′-CN-4-aza-7,9-dideazaadenosine C-nucleoside for the treatment of SARS-CoV-2. Signal Transduction and Targeted Therapy, 2023, 8, 27. 
  13. Qifan Zhou1, Yinzhu Luo1, Yujun Zhu1, Qishu Chen, Jingfei Qiu, Feng Cong*, Yingjun Li*, Xumu Zhang*. Nonsteroidal anti-inflammatory drugs (NSAIDs) and nucleotide analog GS-441524 conjugates with potent in vivo efficacy against coronaviruses. European Journal of Medicinal Chemistry, 2023, 249.
  14. Liu Cao1, Yingjun Li1, Sidi Yang1, Guanguan Li1, Qifan Zhou1, Jing Sun1, et al. The adenosine analogue prodrug ATV006 is orally bioavailable and has potent preclinical efficacy against SARS-CoV-2 and its variants. Science Translational Medicine, 2022, 14, eabm7621. 
  15. Qifan Zhou, Lina Jia, Fangyu Du, Xiaoyu Dong, Wanyu Sun, Lihui Wang, Guoliang Chen*. Design, synthesis and biological activities of pyrrole-3-carboxamide derivatives as EZH2 (enhancer of zeste homologue 2) inhibitors and anticancer agents. New Journal of Chemistry, 2020, 44, 2247-2255. 
  16. Fangyu Du1, Qifan Zhou1, Wenjiao Sun, Cheng Yang, Chunfu Wu, Lihui Wang* and Guoliang Chen*. 5-Hydroxyindole-based EZH2 inhibitors assembled via TCCA-catalyzed condensation and Nenitzescu reactions. Molecules, 2020, 25, 2059–2083.
  17. Qifan Zhou, Fangyu Du, Yuanguang Chen, Yang Fu, Wenjiao Sun, Ying Wu, Guoliang Chen*. L-(-)-Quebrachitol as a ligand for selective copper (0)-catalyzed N‑arylation of nitrogen-containing heterocycles. Journal of Organic Chemistry, 2019, 84, 8160–8167. 
  18. Qifan Zhou, Fangyu Du, Yuanguang Chen, Yang Fu, Guoliang Chen*. “On Water” promoted N-arylation reactions using Cu (0)/myo-inositol catalytic system. Tetrahedron Letters, 2019, 60, 1938–1941. 
  19. Chunling Yuan1, Xiaoli Guo1, Qifan Zhou1, Fangyu Du, Xiaoyu Zhou, Peng Liu, Tianyan Chi, Xuefei Ji, Jinheng Gao, Chengwen Chen, Hongli Lang, Jia Xu, Danyang Liu, Yang Yang, Shimeng Qiu, Guoliang Chen* and Libo Zou*. OAB-14, a novel small molecule, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing -amyloid clearance in APP/PS1 mice. BBA-Molecular Basis of Disease, 2019, 1865, 161–180. 
  20. Yajie Shi1, Qifan Zhou1, Fangyu Du, Yang Fu, Yang Du, Ting Fang and Guoliang Chen*. Iridium-catalyzed intramolecular C-N and C-O/S cross-coupling reactions: Preparation of benzoazole derivatives. Tetrahedron Letters, 2019, 60, 151082–151090. 
  21. Fangyu Du1, Qifan Zhou1, Yang Fu, Yuanguang Chen, Ying Wu* and Guoliang Chen*. Copper(II)-catalyzed C–N coupling of aryl halides and N-nucleophiles promoted by quebrachitol or diethylene glycol. Synlett, 2019, 30, 2161–2168. 
  22. Fangyu Du1, Qifan Zhou1, Yang Fu, Hanqi Zhao, Yuanguang Chen and Guoliang Chen*. tert-Butyl(3-cyano-4,6-dimethylpyridin-2-yl)carbonate as a green and chemoselective N–tert-butoxycarbonylation reagent. New Journal of Chemistry, 2019, 43, 6549–6554. 
  23. Fangyu Du, Qifan Zhou, Xiaoxiao Fu, Yajie Shi, Yuanguang Chen, Wuhong Fang, Jingyu Yang* and Guoliang Chen*. Synthesis and biological evaluation of 2,2-dimethylbenzopyran derivatives as potent neuroprotection agents. RSC Advances, 2019, 9, 2498–2508. 
  24. Fangyu Du, Qifan Zhou, Wenjiao Sun and Guoliang Chen*. Targeting cancer stem cells in drug discovery: Current state and future perspectives. World Journal of Stem Cells, 2019, 11, 398–420. 
  25. Fangyu Du, Qifan Zhou, Yajie Shi, Miao Yu, Wenjiao Sun and Guoliang Chen*. Synthesis of regorafenib through novel preparation of the intermediate 4-amino-3-fluorophenol via fries and Beckman rearrangements. Synthetic Communications, 2019, 49, 576–586. 
  26. Caijiao Wu1, Qifan Zhou1, Dake Song, Hui Li, Changshun Bao, Xuelong Liu, Xuefei Bao and Guoliang Chen*. An improved process for the preparation of pimavanserin tartrate. Journal of Chemical Research, 2019, 43, 480-485. 
  27. Qifan Zhou, Chen Peng, Fangyu Du, Linbo Zhou, Yajie Shi, Yang Du, Dongdong Liu, Wenjiao Sun, Meixia Zhang*, Guoliang Chen*. Design, synthesis and activity of BBI608 derivatives targeting on stem cells. European Journal of Medicinal Chemistry, 2018, 151, 39-50. 
  28. Qifan Zhou, Fangyu Du, Xinjie Liang, Wenqiang Liu, Ting Fang and Guoliang Chen*. Zinc (II)-mediated selective O-benzylation of 2-oxo-1,2-dihydropyridines systems. Molecules, 2018, 23, 1784-1798. 
  29. Qifan Zhou, Fangyu Du, Yajie Shi, Wenqiang Liu, Dongdong Liu and Guoliang Chen*. An efficient protocol for the production of pymetrozine via a new synthetic strategy. Journal of Chemical Research, 2018, 42, 395-446. 
  30. Qifan Zhou, Fangyu Du, Yajie Shi, Ting Fang, Guoliang Chen*. The synthesis and analysis of 1-methyl-4-phenyl-1H-imidazol-2-amine and by-products. Journal of Chemical Research, 2018, 42, 608–610. 
  31. Fangyu Du, Qifan Zhou, Dongdong Liu, Ting Fang, Yajie Shi, Yang Du, Guoliang Chen*. Dimerization of aromatic compounds using palladium-carbon catalyzed Suzuki–Miyaura cross-coupling by one-pot synthesis. Synlett, 2018, 29, 779-784.